Literature DB >> 17876301

Is there a functional correlate of Kv1.5 in the ventricle of canine heart and what would it mean for the use of I(Kur) blockers?

E Wettwer1.   

Abstract

The cardiac ultrarapid outward current I(Kur), encoded by KCNA5, is of special pharmacological interest, because it is considered to be atrium-specific. I(Kur) has therefore become a target in the therapy of atrial tachyarrhythmias. However, the concept of atrium specificity is only valid if a functional I(Kur) current is in fact absent from the ventricle. However, new work has detected a I(Kur)-like current in canine ventricular myocytes, sensitive to 4-aminopyridine and suppressed by the I(Kur) blocker DPO-1, findings that support the existence of a functional ventricular I(Kur). These indications are, however, indirect and more effort is needed to clarify unequivocally the putative role of an expectedly small I(Kur) component in the ventricle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876301      PMCID: PMC2078221          DOI: 10.1038/sj.bjp.0707463

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

Review 1.  Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium.

Authors:  J M Nerbonne
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

2.  Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle.

Authors:  M M Tamkun; K M Knoth; J A Walbridge; H Kroemer; D M Roden; D M Glover
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

3.  In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.

Authors:  Gary L Stump; Audrey A Wallace; Christopher P Regan; Joseph J Lynch
Journal:  J Pharmacol Exp Ther       Date:  2005-09-12       Impact factor: 4.030

4.  Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.

Authors:  Ulrich Schotten; Sunniva de Haan; Sander Verheule; Erik G A Harks; Dirk Frechen; Eva Bodewig; Maura Greiser; Rashmi Ram; Jos Maessen; Malte Kelm; Maurits Allessie; David R Van Wagoner
Journal:  Cardiovasc Res       Date:  2006-11-23       Impact factor: 10.787

5.  Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes.

Authors:  J Feng; B Wible; G R Li; Z Wang; S Nattel
Journal:  Circ Res       Date:  1997-04       Impact factor: 17.367

6.  Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes.

Authors:  L Yue; J Feng; Z Wang; S Nattel
Journal:  J Physiol       Date:  1999-04-15       Impact factor: 5.182

7.  Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block.

Authors:  Avram Oros; Paul G A Volders; Jet D M Beekman; Theo van der Nagel; Marc A Vos
Journal:  Heart Rhythm       Date:  2006-07-20       Impact factor: 6.343

8.  Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.

Authors:  Nathalie Gaborit; Sabrina Le Bouter; Viktoria Szuts; Andras Varro; Denis Escande; Stanley Nattel; Sophie Demolombe
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

9.  Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.

Authors:  David Fedida; Jodene Eldstrom; J Christian Hesketh; Michelle Lamorgese; Laurie Castel; David F Steele; David R Van Wagoner
Journal:  Circ Res       Date:  2003-09-18       Impact factor: 17.367

10.  Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.

Authors:  Armando Lagrutta; Jixin Wang; Bernard Fermini; Joseph J Salata
Journal:  J Pharmacol Exp Ther       Date:  2006-03-07       Impact factor: 4.030

View more
  3 in total

1.  Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure.

Authors:  H-J Schneider; O Husser; M Rihm; S Fredersdorf; C Birner; S Dhein; F Muders; A Jeron; H Goegelein; G A Riegger; A Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-30       Impact factor: 3.000

2.  Polyunsaturated Fatty acids modify the gating of kv channels.

Authors:  Cristina Moreno; Alvaro Macias; Angela Prieto; Alicia De La Cruz; Carmen Valenzuela
Journal:  Front Pharmacol       Date:  2012-09-10       Impact factor: 5.810

3.  The Pattern of mRNA Expression Is Changed in Sinoatrial Node from Goto-Kakizaki Type 2 Diabetic Rat Heart.

Authors:  F C Howarth; M A Qureshi; P Jayaprakash; K Parekh; M Oz; H Dobrzynski; T E Adrian
Journal:  J Diabetes Res       Date:  2018-09-02       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.